INmune Advances RDEB Therapy Toward UK Approval, Eyes Pediatric Incentive
Event summary
- INmune Bio submitted a pre-submission package for CORDStrom™ to the UK MHRA for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
- The pre-submission process aims to streamline the full Marketing Authorization Application (MAA) and accelerate potential approval.
- Commercial-scale manufacturing runs at the CGT Catapult facility have confirmed product readiness.
- INmune anticipates filing a full MAA in mid-summer 2026, followed by US submissions in Q4 2026.
- The reauthorization of the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029 could provide a significant incentive for US approval.
The big picture
The advancement of CORDStrom™ represents a significant opportunity to address a severe unmet medical need in RDEB, a debilitating condition affecting approximately 1 in 1 million births. The pre-submission strategy highlights a growing trend among biopharma companies to engage with regulators early in the approval process. The reauthorized PRV program underscores the government’s commitment to incentivizing therapies for rare pediatric diseases, potentially accelerating commercialization and boosting investor returns.
What we're watching
- Regulatory Response
- The MHRA’s feedback on the pre-submission package will be critical in shaping the timeline and potential requirements for full approval, and will reveal the agency’s appetite for novel cell therapies in rare diseases.
- Manufacturing Scale
- While initial manufacturing runs have been successful, sustained, large-scale production of CORDStrom™ will be essential to meet potential demand and avoid supply chain bottlenecks post-approval.
- PRV Utilization
- INmune’s ability to secure and utilize the Rare Pediatric Disease Priority Review Voucher will significantly impact the speed of US approval and the company’s overall valuation.
Related topics